Physician profile
Walter Pugh
NPI 1770632762
$10,180.99
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,434 · 2020: $1,916 · 2021: $2,475 · 2022: $2,102 · 2023: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,295.64 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $870.48 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.03 | 2019-2023 | Jardiance, Glyxambi, Synjardy |
| Astrazeneca Pharmaceuticals LP | $684.45 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $621.54 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $596.93 | 2019-2023 | |
| Dexcom, INC. | $544.19 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $539.39 | 2019-2022 | |
| Lilly USA, LLC | $446.43 | 2019-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $428.44 | 2019-2023 | |
| Glaxosmithkline, LLC. | $384.48 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $355.30 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.59 | 2020-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $267.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $261.01 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Pugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.